With respect to GLP-1RAs, liraglutide and semaglutide have demonstrated a reduction in the risk of major adverse cardiovascular events (MACE) [16, 17], and, while yet not published, early reports for dulaglutide indicate CV benefits in patients with a wide range of CV risk [18]
Humphries was there and saved my life, Vera said
Diagnostic accuracy of interleukin-6 and interleukin-8 in predicting severe acute pancreatitis: a meta-analysis
Still, further studies are needed to confirm this risk, and causality has not been established
American journal of public health, 90(2), 251
IV delivery bypasses your digestive system entirely, sending every ingredient directly into your bloodstream at near-100% bioavailability, a level no oral supplement can match